The association of FKBP51 with stress-related disorders and neurodegenerative diseases, together with the protective effects seen with FKBP51 depletion in animal models of depression and anxiety make this co-chaperone a promising drug target. This evidence concerns the gene FKBP4 and neurodegenerative disease.